Ruxolitinib and Methylprednisolone as First Line Therapy for Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Methylprednisolone (Primary) ; Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
Most Recent Events
- 30 Sep 2024 Status changed from not yet recruiting to discontinued.
- 15 Oct 2018 New trial record
- 12 Oct 2018 Planned End Date changed from 30 Sep 2021 to 31 Oct 2021.